Treatment with ROCK inhibitors and genetic ablation of ROCK1 have also been shown to ameliorate inflammation and fibrosis in rodent models of NASH, as well as hepatic steatosis and insulin resistance (79, 80). Here, ROCK1 is linked to fatty liver disease.